AKT1 and ovarian carcinoma: Concomitant treatment with TTFields and the PI3K inhibitor alpelisib reduced AKT (Ser473) phosphorylation and enhanced TTFields efficacy across tumor types, as demonstrated in vitro for GBM, ovarian cancer, and lung cancer models, and in vivo for ovarian and lung cancer models.